Clinical Pharmacology & Biopharmaceutics
Open Access

Research Article

Beneficial Effect of a Multifunctional Polyphytocompound in Experimental Prostatic Hyperplasia in Rats

¹ReGenera Research Group for Aging Intervention and San Babila Clinic, Milano, Italy

²ICAR-Indian Veterinary Research Institute, Regional Station, Palampur, Himachal Pradesh, India

³Department of Geriatrics and Gerontology, Ain Shams University, Cairo, Egypt

⁴Department of Agriculture and Food Supply, São Paulo Agency for Agribusiness Technology, University of São Paulo, São Paulo, Brazil

⁵Department of Nutrition, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil

⁶Department of Life Sciences, Shri Venkateshwara University, JP Nagar, Uttar Pardesh, India

⁷WHO-Centre for Traditional Medicine and Biotechnology, University of Milano, Italy

*Corresponding Author:

Francesco Marotta
ReGenera Research Group for Aging Intervention and San Babila Clinic
Corso Matteotti, 1/A 20121 Milano, Italy
Tel: +39-024077243
E-mail: fmarchimede@libero.it

Received Date: February 27, 2017; Accepted Date: March 24, 2017; Published Date: March 27, 2017

Citation: Kantah M, Singh B, Sweed H, Neto GB, Kumar N, et al. (2017) Beneficial Effect of a Multifunctional Polyphytocompound in Experimental Prostatic Hyperplasia in Rats. Clin Pharmacol Biopharm 6:169. doi: 10.4172/2167-065X.1000169

Copyright: © 2017 Kantah M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

The aim of the present study was to assess the efficacy of a poly-phytocompound in a model of experimental BPH. Adult 8 weeks male Wistar rats were subjected to complete orchiectomy under anesthesia (i.p. injection of 100 mg/kg body weight of sodium pentobarbital). After castration, experimental BPH was reproduced by subcutaneous injection of testosterone (20 mg/kg) for 4 weeks and, at the same time, rats randomly divided in 3 groups (15 rats each): (A) untreated BPH model; (B) BPH plus TR10/P3795 orally and (C) BPH plus finasteride (10 mg/kg body weight) administered orally as positive control group. A third group (D) of sham-operated rats served as control. Both TR10/P3795- and finasteride-treated groups showed a significant (p<0.05) and comparable reduction of all morphometric parameters (volume, weight and weight/body weight ration) which were grossly abnormal in untreated BPH model (p<0.01 vs. sham-op.). Moreover, both treatment schedule maintained a near-to-normal 3 h urinary output (p<0.01 vs. untreated BPH). Untreated BPH showed a significant increase of epithelial size and thickness and these features were equally decreased by TR10/P3795 and finasteride (p<0.05). Either TR10/P3795 or finasteride brought about a significant decrease of serum level of DHT and PAP (p<0.05 vs. sham). There was no difference among the two treatments. Prostatic tissue concentration of MDA, IL-6, TNFα and TGFβ1 significantly increased in untreated BPH model (p<0.001). All these parameters significantly decreased, although not normalised, in TR10/P3795-treated group (p<0.05 vs. sham and vs. finasteride). Finasteride determined only a not significant trend decrease of IL-6 and TNFα. Given the multifactorial aetiology of BPH, the data from this experimental model show the promising larger spectrum of mechanisms of action of the tested poly-phytocompound.

Keywords